Sector Gamma AS Trims Stock Position in Qiagen N.V. $QGEN

Key Points

• Sector Gamma AS has reduced its stake in Qiagen N.V. by 37.4%, now owning 117,000 shares, which accounts for about 1.8% of its portfolio.
• Qiagen reported a quarterly earnings per share of $0.60, meeting analysts' expectations, with a year-over-year revenue increase of 7.7%.
• Research firms have mixed ratings on Qiagen, with UBS setting a price target of $50.00 and Barclays at $53.00, while the average consensus remains at a "Hold" rating with a target price of $49.69.

Sector Gamma AS reduced its stake in shares of Qiagen N.V. (NYSE:QGEN - Free Report) by 37.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 117,000 shares of the company's stock after selling 70,000 shares during the quarter. Qiagen comprises approximately 1.8% of Sector Gamma AS's portfolio, making the stock its 21st largest holding. Sector Gamma AS owned about 0.05% of Qiagen worth $5,623,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the stock. Voya Investment Management LLC increased its position in Qiagen by 52.3% during the first quarter. Voya Investment Management LLC now owns 245,657 shares of the company's stock worth $9,845,000 after buying an additional 84,332 shares during the period. US Bancorp DE grew its position in shares of Qiagen by 16.6% during the second quarter. US Bancorp DE now owns 66,901 shares of the company's stock worth $3,215,000 after acquiring an additional 9,544 shares during the last quarter. Farther Finance Advisors LLC grew its position in shares of Qiagen by 400.5% during the second quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company's stock worth $51,000 after acquiring an additional 849 shares during the last quarter. Callan Family Office LLC acquired a new position in shares of Qiagen in the 2nd quarter valued at $304,000. Finally, GAMMA Investing LLC raised its position in Qiagen by 93.9% in the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after purchasing an additional 1,425 shares during the last quarter. Institutional investors and hedge funds own 70.00% of the company's stock.

Qiagen Stock Performance

NYSE:QGEN opened at $49.39 on Friday. The firm's fifty day moving average price is $47.00 and its 200 day moving average price is $46.02. Qiagen N.V. has a 1-year low of $37.63 and a 1-year high of $51.88. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35. The firm has a market cap of $10.98 billion, a price-to-earnings ratio of 29.18, a price-to-earnings-growth ratio of 2.55 and a beta of 0.66.

Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, meeting analysts' consensus estimates of $0.60. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The firm had revenue of $533.54 million for the quarter, compared to analyst estimates of $523.97 million. During the same period last year, the firm posted $0.55 EPS. Qiagen's quarterly revenue was up 7.7% on a year-over-year basis. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, sell-side analysts expect that Qiagen N.V. will post 2.26 EPS for the current year.

Wall Street Analysts Forecast Growth

QGEN has been the topic of several research reports. UBS Group raised their price objective on shares of Qiagen from $48.00 to $50.00 and gave the stock a "neutral" rating in a research report on Thursday, August 7th. Barclays set a $53.00 target price on shares of Qiagen and gave the stock an "overweight" rating in a research note on Thursday, October 2nd. Weiss Ratings restated a "hold (c+)" rating on shares of Qiagen in a research report on Wednesday, October 8th. Wall Street Zen downgraded Qiagen from a "buy" rating to a "hold" rating in a research note on Saturday, October 11th. Finally, Cowen reiterated a "hold" rating on shares of Qiagen in a research note on Thursday, August 7th. Three investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $49.69.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.